19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2525



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Helping Ease Kids' Fears After Manchester Terror AttackOverweight in Childhood May Up Lifetime Risk of DepressionOverweight Boys Face Higher Colon Cancer Risk as AdultsHeavy Kids Face Triple the Odds for Depression in AdulthoodHealth Tip: Limit a Young Child's Media TimeMany Parents Underestimate Drowning RisksChildren Express Positive Views of Digital Tracking by StrangersToo Many Parents Say No to Helmets for Kids on WheelsHear This! Keep Cotton Swabs Out of Kids' EarsHealth Tip: Be a Safe Driver for Your Kids'Dr. Google' May Undermine Parents' Trust in Their PediatricianPAS: Hospitalizations Up for Suicidal Thoughts, Actions in KidsGuns Send About 16 U.S. Kids to the Hospital Every DayWhen Grandparents Raise Grandkids, Are They Up to Date on Child Safety?More Starring Roles for Booze in Kids' Movies, Study FindsThe Family That Eats Together, BenefitsAre Smartphones Helping or Harming Kids' Mental Health?More Active Kids Could Save U.S. Billions in Health Costs: StudyTrump Administration Rolls Back Obama-Era School Lunch RulesAre Bullies Getting Run Out of U.S. Schools?Health Tip: Turn Off Those ScreensKids' Sun Safety Means 'Slip, Slap, Slop'Pediatricians Missing Elevated Blood Lead Levels in U.S.AAP Stresses Medical Home Best for Acute Health ConcernsAre Kids' Vaccines a Victim of Their Own Success?Checklist for Family-Centered Rounds Deemed BeneficialChildren With Suspected Child Abuse Present to Hospital LateCancer Risk Rises After Childhood Organ Transplant: StudyModel Predicts Which Pediatric ER Patients Likely to Be AdmittedObesity Quadruples Kids' Type 2 Diabetes Risk: StudyAre You Raising an 'Emotional Eater'?More Risks on School Playgrounds Linked to Happier ChildrenKids Face Their Own Death Risks When a Sibling DiesIn America's Poorest Communities, a Greater Risk of Child Abuse DeathsFDA Warns Against Children Taking Codeine, TramadolNext Seven Great Achievements in Pediatric Research PredictedMany Students Reluctant to Use Asthma Inhalers at SchoolDon't Give Kids Medicines With Codeine, Tramadol: FDAMany Kids Still Being Injured on ATVsHypnosis Doesn't Improve Post-Op Anxiety, Pain in ChildrenHealth Tip: Minimizing Violence During Screen TimeHealth Tip: Concerned About Your Child's Weight?What's the Best Seasonal Allergy Med for Your Kid?Web-Based Platform Better for Delivering Pre-Op InformationKids Can Pick Up Nicotine on Their HandsHealth Tip: Checking Your Child's MolesCould a Clinical Trial Help Your Child?Direct-Acting Antivirals Approved for Children 12+ With HCVWhen Families Lack Insurance, Kids' Dental Woes Rise10 Minutes of Sweat a Day Helps Kids' Hearts
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

Direct-Acting Antivirals Approved for Children 12+ With HCV


HealthDay News
Updated: Apr 10th 2017

new article illustration

MONDAY, April 10, 2017 (HealthDay News) -- The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C virus (HCV) infection in children aged 12 and older.

Sovaldi (sofosbuvir) and Harvoni (ledipasvir, sofosbuvir) are the first direct-acting antiviral treatments approved for children and adolescents with HCV, the agency said in a news release Friday.

The two approvals provide pediatric treatment options for six major genotypes of HCV: Harvoni is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 1, 4, 5, or 6 infection without cirrhosis or with mild cirrhosis. Sovaldi in combination with ribavirin is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 2 or 3 infection without cirrhosis or with mild cirrhosis.

In clinical studies, the most common side effects of both drugs were fatigue and headache. Health care professionals should screen all patients for evidence of current or prior hepatitis B virus infection before starting treatment with Harvoni or Sovaldi, the agency advised.

"These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents," Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

Harvoni and Sovaldi are marketed by Gilead Sciences, in Foster City, Calif.

More Information